Cytokinetics Incorporated (NASDAQ:CYTK) on Friday shared primary results from the ACACIA-HCM Phase 3 clinical trial of aficamten in patients with symptomatic non-obstructive hypertrophic cardiomyopathy (nHCM).
The data showed aficamten significantly improved symptoms and exercise performance in patients suffering from symptomatic non-obstructive hypertrophic cardiomyopathy.
Meeting Primary Endpoints
The ACACIA-HCM clinical study successfully achieved its dual primary endpoints. Researchers observed substantial enhancements in patients over 36 weeks when comparing the active treatment to a placebo.
Trial participants reported notably better scores on the Kansas City Cardiomyopathy Questionnaire Clinical Summary Score, indicating a reduction in disease symptoms.
Patients also displayed increased maximal exercise performance. Furthermore, these positive findings remained consistent across all predetermined patient subgroups evaluated during the study.
Evaluating Broad Clinical Benefits
During the European Society of Cardiology Congress 2026 in Munich, researchers presented an additional assessment detailing the overall effectiveness of the treatment across five vital medical areas.
These domains included exercise capacity, cardiac structure, cardiac biomarkers, diastolic function, and overall symptom burden.
At the 36-week mark, individuals taking aficamten demonstrated statistically significant progress in all five categories compared to the placebo group.
Notably, 53% of the treated patients achieved a clinical response in three or more measurement areas, whereas only 13% of the placebo group reached the same milestone.
Stock Reaction
Citing analysts, Reuters noted that the drug did not significantly improve heart structure or delay cardiovascular events.
About 10% of the patients also experienced a drop in their heart’s pumping capacity, and 12 events of heart failure also occurred during the study.
“Investors might be reacting to the size of the win, not whether it won,” B. Riley Securities analyst Mayank Mamtani told Reuters.
“There was an imbalance of heart failure events early on in the study,” Cytokinetics Chief Medical Officer Stephen Heitner told Reuters.
Regulatory Next Steps
Medical professionals simultaneously published the primary data in The New England Journal of Medicine and the sub-analysis in Circulation.
Cytokinetics intends to file a supplemental New Drug Application with the U.S. Food and Drug Administration in the fourth quarter of 2026 for symptomatic non-obstructive hypertrophic cardiomyopathy.
CYTK Price Action: Cytokinetics shares were down 3.19% at $69.79 at the time of publication on Monday, according to Benzinga Pro data.
Photo by Chinnapong via Shutterstock
Login to comment